Hospira reports Q2 sales, announces clinical trial for biosimilar
LAKE FOREST, Ill. Hospira had net sales of $968 million and profits of $83.5 million in second quarter 2010, the generic drug maker said in an earnings report.
That compared with second-quarter sales of $957 million and profits of $25.5 million.
“Hospira delivered another solid quarter, driven by strong performance in our specialty injectable pharmaceuticals business and by continued momentum of our Project Fuel optimization initiatives,” chairman and CEO Christopher Begley said. “We made significant progress in advancing our during the quarter, launching our first product from Hospira India, commercializing our second biosimilar product in Europe and strengthening our position in acute-care proprietary pharmaceuticals.”
The company also announced that the start of an early-stage clinical trial of biosimilar erythropoietin in patients with kidney dysfunction and anemia, which it called an important step toward the introduction of a biosimilar in the United States. The drug is a follow-on version of Amgen’s Epogen (epoetin alfa). Hospira hopes to launch a phase 3 trial of the drug next year. It already sells a version of the drug in Europe under the name Retacrit, which it introduced in 2008.
Smiling Planet announced partnership with Healthy Child Healthy World
LOS ANGELES Smiling Planet a new line of earth-friendly lifestyle products for kids, has joined the Healthy Child Healthy World network.
The partnership represents a joint commitment to raising awareness about preventing children’s exposure to harmful chemicals, and also reinforces the high standards of safety, quality, and environmental consciousness that Smiling Planet sets for its children’s dinnerware. Smiling Planet’s plates and bowls are specifically designed to be a safe and practical alternative to dinnerware containing melamine, BPA and other harmful chemicals, Smiling Planet said.
“Today’s parents are inundated with conflicting information about product safety, often leaving them unsure about which products are best,” said Freddy Deane, who co-founded Smiling Planet with wife Olivia Haviland. “We’re proud to join Healthy Child Healthy World to empower parents to find the safest possible products for their children, and for the planet.”
Sagent’s generic Imitrex receives regulatory approval
SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.
The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.
Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.